奥雷巴替尼联合奥加伊妥珠单抗治疗多次复发Ph阳性急性淋巴细胞白血病1例OA
Olverembatinib combined with inotuzumab ozogamicin in Philadelphia chromosome-positive acute lymphoblastic leukemia with multiple relapses:a case report
复发/难治性(relapsed/refractory,R/R)费城染色体阳性急性淋巴细胞白血病(Philadelphia chromosome-positive acute lymphoblastic leukemia,Ph+ALL)治疗困难,预后差,总生存期较短.酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)及免疫治疗为此类患者带来了新的治愈希望.本文回顾性分析 1例多次复发的 Ph+ALL患者,经奥雷巴替尼联合减量奥加伊妥珠单抗治疗,2个月后复查达完全缓解(complete response,CR),微小残留病灶(minimal residual disease,MRD)阴性,基本达完全分子学缓解(complete molecular response,CMR),以期为临床提供治疗经验.
Relapsed/refractory(R/R)Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph+ALL)is difficult to treat,facing a poor prognosis and short overall survival.The usage of tyrosine kinase inhibitor(TKI)and immunotherapy has brought new hope for the treatment of R/R Ph+ALL for patients.This paper retrospectively analyzed a patient with Ph+ALL experiencing multiple relapses,who was treated with olverembatinib in combination with a reduced dose of inotuzumab ozogamicin.The patient achieved complete response(CR)and minimal residual disease(MRD)negativity upon reexamination two months later,attaining a near-complete molecular response(CMR).A review of relevant literature is included to provide clinical treatment experience.
刘恒;葸瑞;潘耀柱;王宗慧;田红娟;毛东锋;吴涛
中国人民解放军联勤保障部队第九四〇医院血液科,甘肃 兰州 730050中国人民解放军联勤保障部队第九四〇医院血液科,甘肃 兰州 730050中国人民解放军联勤保障部队第九四〇医院血液科,甘肃 兰州 730050中国人民解放军联勤保障部队第九四〇医院血液科,甘肃 兰州 730050中国人民解放军联勤保障部队第九四〇医院血液科,甘肃 兰州 730050中国人民解放军联勤保障部队第九四〇医院血液科,甘肃 兰州 730050中国人民解放军联勤保障部队第九四〇医院血液科,甘肃 兰州 730050
医药卫生
奥雷巴替尼奥加伊妥珠单抗复发难治费城染色体阳性急性淋巴细胞白血病
olverembatinibinotuzumab ozogamicinrelapsed/refractoryPhiladelphia chromosome-positive acute lymphoblastic leukemia
《内科理论与实践》 2026 (1)
59-61,3
兰州市青年科技人才创新项目(2023-QN-16)甘肃省重点研发计划(22YF7FA106)联勤保障部队第九四〇医院血液病医学研究中心项目(2021yxky078)甘肃省科技计划项目(21JR7RA015、22YF7FA106、23JRRA535、25JRRA1184)
评论